Hunan Agen Lab PD-L1 LDT Service
Singapore-based Biolidics said its laboratory partner, Hunan Agen Medicine Laboratory Technology, has launched a commercial laboratory-developed testing service in China using Biolidics' ClearCell FX1 System and CTChip FR1 biochip for testing of PD-L1 status in cancer patients. In March, Hunan Agen Lab began offering an LDT service related to circulating tumor cells. According to a Biolidics spokesman, the earlier service was for post-treatment monitoring and prognosis of patients, while the service launched now includes treatment selection. Biolidics was previously called ClearBridge Biomedics and changed its name in conjunction to listing on the Singapore Exchange.